HTB South

CROI 21 (Retrovirus) Boston 2014

21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014, Boston

No HIV transmissions with undetectable viral load: interim PARTNER study results show need for longer follow-up

PrEP injections every three months may protect against exposure from anal sex

ARV pipeline: doravirine, GSK-744 and BMS-068

Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study

Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r

Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257

Pharmacokinetic targets for efavirenz might be too high

Abacavir link to cardiovascular events in high-risk patients maintained in D:A:D study

NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs

HIV related infections remain the leading cause of maternal deaths in South Africa despite the availability of ART

Lower newborn bone mineral content with maternal tenofovir use

Paediatric pipeline: CROI 2014 update on new antiretrovirals for children

Efavirenz maintenance therapy effective in children exposed to nevirapine prophylaxis

Xpert TB test has important advantages but does not reduce morbidity

Moxifloxacin and rifapentine: we need better trials

Trials show further benefits for cotrimoxazole in children and adults

Reports of a second baby possibly cured of HIV: uncertainty remains

Updates on SB728-T, a CCR5-targeting gene therapy